Sharon O'Kane, Ph.D. was appointed to LivaNova's Board in October 2015. Currently, Dr. O'Kane is the Entrepreneur in Residence at University College Dublin and is on the clinical/scientific advisory board of ScarX Therapeutics Inc., a Canadian biotech company. Dr. O'Kane is an expert advisor to the Stevenage Bioscience Catalyst Facility at GSK. Previously, Dr. O'Kane served on the board of directors at IOmet Pharma LTD from April 2010 until January 2016. Additionally, Dr. O'Kane was the Entrepreneur in Residence at the University of Manchester Intellectual Property Company UMIP from 2009 to 2014, and the Chair of the Drug Discovery Advisory Board at the University of Manchester from 2011 to 2013. From 2011 to 2013, she was also a member of the External Business Advisory Board of the Faculty of Life Sciences of the University of Manchester, and from 2010 to 2012, Dr. O'Kane was a non-executive director of Manchester Inward Development Agency and a member of the Operational Board of the Association of Greater Manchester Authorities' Centre of Excellence. Dr. O'Kane co founded, and from 1998-2010 was the Chief Scientific Officer and Executive Director of Renovo Group PLC (“Renovo''), a publicly listed U.K. biotech company. Dr. O'Kane has been a member of the Institute of Directors since 2002, and has a diploma in Company Direction from the Institute of Directors. Dr. O'Kane's particular qualifications for service on our Board include her extensive experience in the healthcare arena in both academic and research capacities, service on the boards of other biotech and healthcare companies, her roles as co-founder, Chief Scientific Officer and Executive Director of Renovo and numerous positions advising healthcare and biotech companies.